Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMS001
MIFTS: 46

Hemosiderosis

Categories: Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hemosiderosis

About this section

MalaCards integrated aliases for Hemosiderosis:

IMPROVED
Name: Hemosiderosis 11 19 75 53 43 14 71
Haemosiderosis 11
Iron Overload 71

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:12119
MeSH 43 D006486
SNOMED-CT 68 39011001
UMLS 71 C0019114 C0282193
Sources

Summaries for Hemosiderosis

About this section

Disease Ontology: 11 An iron metabolism disease that has material basis in an accumulation of hemosiderin, an iron-storage complex, resulting in iron overload.

MalaCards based summary: Hemosiderosis, also known as haemosiderosis, is related to rare hereditary hemochromatosis and aceruloplasminemia. An important gene associated with Hemosiderosis is CP (Ceruloplasmin), and among its related pathways/superpathways are Transport of inorganic cations/anions and amino acids/oligopeptides and HIF-1-alpha transcription factor network. The drugs Orange and Iron have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and heart, and related phenotypes are homeostasis/metabolism and liver/biliary system

GARD: 19 Accumulation of iron in internal organs.

Wikipedia: 75 Hemosiderosis is a form of iron overload disorder resulting in the accumulation of... more...
Sources

Related Diseases for Hemosiderosis

About this section

Diseases related to Hemosiderosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 536)
# Related Disease Score Top Affiliating Genes
1 rare hereditary hemochromatosis 31.2 TFR2 TF SLC40A1 HJV HFE HAMP
2 aceruloplasminemia 30.1 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
3 liver cirrhosis 30.1 TF HP HFE GPT ALB
4 celiac disease 1 30.0 TFRC HP HFE GPT ALB
5 hepatic tuberculosis 30.0 GPT ALB
6 hemoglobinuria 30.0 TFRC HP EPO
7 alcoholic liver cirrhosis 29.9 HFE GPT ALB
8 exanthem 29.9 PRTN3 GPT ALB
9 wilson disease 29.8 HFE GPT CP ALB
10 acute kidney failure 29.7 PRTN3 HP GPT ALB
11 sickle cell anemia 29.7 TFRC HP HAMP EPO ALB
12 chronic kidney disease 29.7 TF HP EPO ALB
13 hemoglobin h disease 29.7 TFRC HAMP ERFE
14 bronchopneumonia 29.6 HP GPT ALB
15 miliary tuberculosis 29.6 GPT ALB
16 cholelithiasis 29.6 HP GPT ALB
17 congenital dyserythropoietic anemia 29.6 HFE HAMP ERFE
18 alcohol use disorder 29.5 TF HFE GPT ALB
19 intracranial berry aneurysm 29.5 HP EPO ALB
20 atransferrinemia 29.5 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
21 hypersplenism 29.5 U2AF1 GPT EPO ALB
22 esophageal varix 29.5 HP GPT CP ALB
23 hemorrhagic disease 29.5 PRTN3 GPT ALB
24 iga glomerulonephritis 29.5 TFRC PRTN3 MIF ALB
25 bilirubin metabolic disorder 29.5 HP GPT EPO CP ALB
26 myelodysplastic syndrome 29.4 U2AF1 TFRC TF HFE EPO
27 kidney disease 29.4 TF PRTN3 HP EPO ALB
28 diamond-blackfan anemia 29.3 U2AF1 TFRC HAMP ERFE EPO
29 liver disease 29.2 TF SLC40A1 HFE GPT CP ALB
30 primary biliary cholangitis 29.2 PRTN3 KRT7 GPT CP ALB
31 beta-thalassemia 29.1 TFRC TFR2 TF HJV HFE HAMP
32 pancytopenia 29.1 U2AF1 HP GPT EPO CP ALB
33 siderosis 29.1 TFRC TF SLC40A1 HFE HAMP GPT
34 alpha-thalassemia 29.1 TFRC HP HFE HAMP EPO
35 arthritis 29.0 TFRC MIF HFE GPT ALB
36 thrombocytopenia 28.9 U2AF1 TFRC HP GPT EPO ALB
37 heart disease 28.8 MIF HP HFE GPT EPO CP
38 diabetes mellitus 28.8 TF MIF HP HFE GPT EPO
39 hereditary spherocytosis 28.7 TFRC HP HFE HAMP ERFE EPO
40 iron metabolism disease 28.7 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
41 hemolytic anemia 28.5 U2AF1 TFRC TF HP HFE HAMP
42 beta-thalassemia intermedia 28.4 TFRC TFR2 HJV HFE HAMP ERFE
43 anemia, sideroblastic, 1 28.4 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
44 iron deficiency anemia 28.4 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
45 nutritional deficiency disease 28.4 TFRC TF SLC11A2 HJV HAMP EPO
46 hypochromic microcytic anemia 28.3 TFRC TF SLC40A1 SLC11A2 HJV HAMP
47 microcytic anemia 28.3 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
48 hemoglobinopathy 28.2 TFRC TFR2 TF HP HFE HAMP
49 sideroblastic anemia 28.2 U2AF1 TFRC TFR2 SLC40A1 HJV HFE
50 porphyria 28.1 TFRC TFR2 SLC40A1 HJV HFE HAMP

Graphical network of the top 20 diseases related to Hemosiderosis:



Diseases related to Hemosiderosis
Sources

Symptoms & Phenotypes for Hemosiderosis

About this section

MGI Mouse Phenotypes related to Hemosiderosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 ALB CAT CMAS CP EPO ERFE
2 liver/biliary system MP:0005370 10.18 ALB CP EPO ERFE HAMP HFE
3 cellular MP:0005384 10.1 ALB CAT CP EPO HFE HP
4 cardiovascular system MP:0005385 10.07 ALB CMAS CP EPO HJV HP
5 immune system MP:0005387 10.03 ALB CMAS CP EPO HAMP HFE
6 hematopoietic system MP:0005397 9.83 CP EPO ERFE HAMP HFE HJV
7 mortality/aging MP:0010768 9.47 ALB CAT CMAS EPO ERFE HAMP
Sources

Drugs & Therapeutics for Hemosiderosis

About this section

Drugs for Hemosiderosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 4
2
Iron Approved Phase 4 7439-89-6 29936
3
Deferasirox Approved, Investigational Phase 4 201530-41-8 214348 5493381
4
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
5
Deferiprone Approved Phase 4 30652-11-0 2972
6
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
7
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
8 Micronutrients Phase 4
9 Vitamins Phase 4
10 Trace Elements Phase 4
11 Protective Agents Phase 4
12 Antioxidants Phase 4
13 Iron Chelating Agents Phase 4
14 Immunosuppressive Agents Phase 4
15 Pharmaceutical Solutions Phase 4
16 Cyclosporins Phase 4
17
Zinc cation Approved, Experimental, Investigational Phase 3 7440-66-6, 23713-49-7 32051
18
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
19
Carbamide peroxide Approved Phase 2, Phase 3 124-43-6
20
Hydroxyurea Approved Phase 3 127-07-1 3657
21
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
22
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
23 Silymarin Phase 2, Phase 3
24 Zinc Supplement Phase 3
25 Chelating Agents Phase 2, Phase 3
26 Calcium, Dietary Phase 2, Phase 3
27 Hormones Phase 2, Phase 3
28 calcium channel blockers Phase 2, Phase 3
29 Vasodilator Agents Phase 2, Phase 3
30 Antihypertensive Agents Phase 2, Phase 3
31 Omega 3 Fatty Acid Phase 2, Phase 3
32 Nigella Phase 2, Phase 3
33
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
34
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
35
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
36 Folate Phase 2
37 Pyridoxal isonicotinoyl hydrazone Phase 2
38 Vitamin B9 Phase 2
39 Vitamin B6 Phase 2
40 Vitamin B Complex Phase 2
41 Vitamin B 6 Phase 2
42 Chrysarobin Phase 2
43 Interleukin 1 Receptor Antagonist Protein Phase 2
44 Antirheumatic Agents Phase 2
45 Hepcidins Phase 2
46 Anti-Infective Agents Phase 2
47
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
48
Nifedipine Approved Phase 1 21829-25-4 4485
49
Acetylcysteine Approved, Investigational Phase 1 616-91-1 581 12035
50
Calcium polycarbophil Approved Phase 1 126040-58-2

Interventional clinical trials:

(show top 50) (show all 201)
# Name Status NCT ID Phase Drugs
1 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02443545 Phase 4 Deferiprone
2 1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) Completed NCT00171301 Phase 4 Deferasirox
3 A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets Completed NCT03372083 Phase 4 Deferasirox
4 A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Completed NCT00845871 Phase 4 deferasirox:
5 Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients Completed NCT00105495 Phase 4 Ferriprox (deferiprone);Desferal (deferoxamine)
6 Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
7 Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy Completed NCT00800761 Phase 4 Deferoxamine and Deferiprone;Deferoxamine
8 An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
9 Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia Completed NCT03591575 Phase 4 Deferiprone oral solution;Placebo
10 A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Completed NCT01546415 Phase 4 Desferasirox
11 Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Completed NCT00564941 Phase 4 deferasirox
12 A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study) Completed NCT00673608 Phase 4 deferasirox
13 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4 ICL670/Deferasirox
14 An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients Completed NCT00117507 Phase 4 Deferasirox
15 A Phase IV , Multicenter ,Open Label ,Non Comparative ,Investigator Initiated Study , Evaluating the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed NCT00452660 Phase 4 Exjade
16 1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. Completed NCT01250951 Phase 4 Deferasirox
17 Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload Completed NCT01335035 Phase 4 deferasirox
18 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present Completed NCT00654589 Phase 4 Deferasirox
19 A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation. Completed NCT01610297 Phase 4 ICL670
20 Effects of Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients With Iron Overload Recruiting NCT02225886 Phase 4 Ascorbic Acid
21 The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Terminated NCT02041299 Phase 4 Deferiprone;Deferoxamine
22 Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group Terminated NCT01818726 Phase 4 ICL670;Chelation;No chelation
23 A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload. Terminated NCT01326845 Phase 4 Deferasirox
24 A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
25 Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Patients With Hereditary Hemochromatosis; a Randomised, Single Blinded Sequential, Cross-over Trial Unknown status NCT01398644 Phase 3
26 Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial Unknown status NCT00999349 Phase 2, Phase 3 Silymarin (LEGALON);Placebo
27 Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months Unknown status NCT00980421 Phase 3
28 A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis Completed NCT00061750 Phase 3 ICL670;deferoxamine
29 Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis. Completed NCT00469560 Phase 3 Deferasirox
30 A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Completed NCT00171171 Phase 3 deferasirox
31 Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis Completed NCT00440986 Phase 2, Phase 3
32 Therapeutic Erythrocytapheresis as Treatment for Hemochromatosis Patients. Completed NCT00202436 Phase 3
33 Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Completed NCT00350662 Phase 3 Deferiprone (L1);Desferrioxamine
34 Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Completed NCT01125254 Phase 2, Phase 3 Amlodipine
35 Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial Completed NCT01395199 Phase 3 Amlodipine
36 Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201 Completed NCT02720536 Phase 3 Deferasirox
37 Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia Completed NCT04292314 Phase 2, Phase 3 Omega 3;Nigella Sativa Oil;Hydroxyurea;Honey;Deferoxamine
38 A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators Completed NCT00235391 Phase 3 Deferasirox
39 A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload Completed NCT00171821 Phase 3 Deferasirox
40 An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload Completed NCT00171210 Phase 3 Deferasirox
41 Prospective Randomized Study Comparing the Effect of Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only on Glycemia in Patients With Dysmetabolic Liversiderosis Completed NCT01045525 Phase 3
42 A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Day Deferoxamine in Patients With Transfusion-dependent Iron Overload Completed NCT01033747 Phase 2, Phase 3 Deferasirox
43 A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriproxâ„¢ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia Completed NCT00529152 Phase 3 Deferiprone
44 Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies Completed NCT01825512 Phase 3 Deferiprone;Deferasirox
45 Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease Completed NCT00943748 Phase 2, Phase 3 deferiprone;placebo
46 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
47 Stroke With Transfusions Changing to Hydroxyurea Terminated NCT00122980 Phase 3 Hydroxyurea
48 Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial Terminated NCT01342705 Phase 3
49 Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS Unknown status NCT03920657 Phase 2 Deferasirox
50 A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload Unknown status NCT01284946 Phase 2 Exjade

Search NIH Clinical Center for Hemosiderosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cyclophosphamide
deferasirox
deferiprone

Cochrane evidence based reviews: hemosiderosis

Sources

Genetic Tests for Hemosiderosis

About this section
Sources

Anatomical Context for Hemosiderosis

About this section

Organs/tissues related to Hemosiderosis:

MalaCards : Liver, Pancreas, Heart, Spleen, Pituitary, Bone, Brain
Sources

Publications for Hemosiderosis

About this section

Articles related to Hemosiderosis:

(show top 50) (show all 2387)
# Title Authors PMID Year
1
Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. 53 62
19579082 2009
2
Hematologic iron analyte values as an indicator of hepatic hemosiderosis in Callitrichidae. 53 62
18366107 2008
3
Study of the eye and lacrimal glands in experimental iron overload in rats in vivo. 53 62
18402083 2008
4
Metastatic carcinomatous cirrhosis and hepatic hemosiderosis in a patient heterozygous for the H63D genotype. 53 62
11473464 2001
5
Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. 53 62
10655270 2000
6
[A case of hereditary ceruloplasmin deficiency with hemosiderosis]. 53 62
10391079 1999
7
[Cerebral hemosiderosis related to hereditary ceruloplasmin deficiency. Clinical familial case study]. 53 62
9773037 1998
8
A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. 53 62
9559983 1998
9
Hereditary ceruloplasmin deficiency with hemosiderosis. 53 62
8641692 1996
10
Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. 53 62
7755360 1995
11
A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. 53 62
7539672 1995
12
Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy. 53 62
8362602 1993
13
The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy. 53 62
1585939 1992
14
Successful treatment of hemosiderosis with regular phlebotomy and recombinant human erythropoietin. Case report and ferrokinetic studies. 53 62
1805491 1991
15
Usefulness of biochemical screening of diabetic patients for hemochromatosis. 53 62
2351033 1990
16
Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy. 53 62
2077417 1990
17
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. 62
36121669 2022
18
Cochlea implantation in patients with superficial hemosiderosis. 62
34931263 2022
19
Celiac disease and idiopathic pulmonary hemosiderosis: a literature review of the Lane-Hamilton syndrome. 62
35912848 2022
20
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS). 62
35570412 2022
21
Pathogenic Idiopathic Extramedullary Hematopoiesis in a Yellow-Collared Macaw (Primolius auricollis). 62
35972874 2022
22
Congenital Infection of Severe Acute Respiratory Syndrome Coronavirus 2 With Intrauterine Fetal Death: A Clinicopathological Study With Molecular Analysis. 62
34553751 2022
23
A 49-year-old man with ischemic cardiomyopathy and persistent hemoptysis for eighteen months. 62
35276072 2022
24
Lane-Hamilton syndrome - Is it really a needle in a haystack? 62
34708697 2022
25
Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. 62
34086873 2022
26
Repeated recurrent intracerebral hemorrhage may be involved in cerebral amyloid angiopathy-related inflammation: An autopsy case. 62
35261085 2022
27
Fumonisin B1 induces hepatotoxicity in mice through the activation of oxidative stress, apoptosis and fibrosis. 62
35143865 2022
28
Adult patients with idiopathic pulmonary hemosiderosis: a comprehensive review of the literature. 62
35179664 2022
29
Hepatic and renal toxicity following the injection of copper oxide nanoparticles (CuO NPs) in mature male Westar rats: histochemical and caspase 3 immunohistochemical reactivities. 62
35739448 2022
30
A RETROSPECTIVE STUDY OF HEPATIC HEMOSIDEROSIS AND IRON STORAGE DISEASE IN SEVERAL CAPTIVE AND FREE-RANGING AVIAN SPECIES. 62
35758588 2022
31
[Heavy metal! A case of severe iron overload and supraventricular arrhythmias in a thalassemia major patient]. 62
35674039 2022
32
High-Grade Fetal Vascular Malperfusion Is Associated With Diffuse Chorionic Hemosiderosis. 62
34962169 2022
33
Association between idiopathic pulmonary hemosiderosis and celiac disease in pediatric patients: A scoping review of the literature over the past 50 years. 62
35088581 2022
34
Puzzling (IRIDA-Like and Hemolytic) Anemia in a Child With Idiopathic Pulmonary Hemosiderosis. 62
34966096 2022
35
Recurrence of idiopathic pulmonary hemosiderosis in adults with childhood onset: A case report and literature review. 62
35307363 2022
36
An Infant With Interstitial Lung Disease of Rare Cause. 62
35526896 2022
37
Late presentation of lane-hamilton syndrome in a 33 year old female: A case report. 62
35754673 2022
38
Spinal dural leaks in patients with infratentorial superficial siderosis of the central nervous system-Refinement of a diagnostic algorithm. 62
33098710 2022
39
Strike while the iron is hot: diagnosis of pediatric idiopathic pulmonary hemosiderosis. 62
35420685 2022
40
The Spectrum of Autoantibodies in Adult Patients With Idiopathic Pulmonary Hemosiderosis: A Brief Review of the Literature. 62
35586354 2022
41
Prevalence of autoantibodies in pediatric patients with idiopathic pulmonary hemosiderosis: a scoping review of the literature in the period 1980-2021. 62
35067768 2022
42
Proposed Pathogenesis of Diffuse Alveolar Hemorrhage in Idiopathic Pulmonary Hemosiderosis. 62
35267072 2022
43
Decreased mobility, lack of social support, haemosiderosis and use of antidepressant medications may predict recurrent venous leg ulcers within 12 months of healing: A prospective longitudinal study. 62
34965772 2022
44
Resolving the equation between mucormycosis and COVID-19 disease. 62
35064406 2022
45
A challenging case of an adolescent and young adult patient with high-risk acute lymphoblastic leukemia: the need for a multidisciplinary approach: a case report. 62
35399095 2022
46
Hemoglobinopathies and COVID-19: The Experience of a Center in Northern Greece. 62
36100258 2022
47
Pandemic created clinical eclipse: hemosiderosis versus COVID-19 pneumonia. 62
34751204 2022
48
Comparative Analysis of Adult Patients With Idiopathic Pulmonary Hemosiderosis and Lane-Hamilton Syndrome: A Systematic Review of the Literature in the Period 1971-2022. 62
35475077 2022
49
Role of computed tomography angiography in the evaluation of haemoptysis in children: Decoding the abnormal vessels. 62
36124510 2022
50
Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach. 62
34491458 2022
Sources

Variations for Hemosiderosis

About this section
Sources

Expression for Hemosiderosis

About this section
Search GEO for disease gene expression data for Hemosiderosis.
Sources

Pathways for Hemosiderosis

About this section

Pathways related to Hemosiderosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transport of inorganic cations/anions and amino acids/oligopeptides 66
Show member pathways
 13.14 TFRC TFR2 TF SLC40A1 SLC11A2 HFE
2
HIF-1-alpha transcription factor network 61
11.48 TFRC TF EPO CP
3
Insulin receptor recycling 66
Show member pathways
 11.39 TFRC TFR2 TF SLC40A1 SLC11A2 HFE
4
Ferroptosis 74
11.36 TFRC TF SLC40A1 SLC11A2 CP
5
3q29 copy number variation syndrome 74
11.15 TFRC TF SLC40A1 HFE HAMP
6
Iron metabolism in placenta 74
10.4 TFR2 SLC40A1 SLC11A2
7
Hfe effect on hepcidin production 74
10.28 HJV HFE HAMP
8
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages) 66
Show member pathways
 10.03 SLC40A1 CP
Sources

GO Terms for Hemosiderosis

About this section

Cellular components related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.41 ALB CAT CP EPO ERFE HAMP
2 extracellular space GO:0005615 10.07 ALB CAT CP EPO ERFE GPT
3 recycling endosome GO:0055037 9.92 TFRC TF SLC11A2 HFE
4 blood microparticle GO:0072562 9.85 ALB CP HP TF TFRC
5 basal part of cell GO:0045178 9.73 TF SLC11A2 HFE
6 HFE-transferrin receptor complex GO:1990712 9.32 TFRC TFR2 TF HJV HFE

Biological processes related to Hemosiderosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.26 TFRC SLC40A1 MIF EPO CAT ALB
2 response to hypoxia GO:0001666 10.15 TFRC SLC11A2 EPO CAT
3 aging GO:0007568 10.14 TFRC HAMP EPO CAT
4 acute-phase response GO:0006953 10.07 EPO HAMP HP TFR2 TFRC
5 establishment of localization in cell GO:0051649 10.05 ERFE HAMP SLC11A2 SLC40A1
6 response to iron ion GO:0010039 9.96 HAMP HFE SLC11A2 TFR2 TFRC
7 response to vitamin A GO:0033189 9.93 HAMP EPO CAT
8 multicellular organismal iron ion homeostasis GO:0060586 9.92 SLC40A1 SLC11A2 HFE HAMP
9 iron ion transmembrane transport GO:0034755 9.91 SLC40A1 SLC11A2 HAMP
10 iron ion transport GO:0006826 9.9 TFRC TFR2 TF SLC40A1 SLC11A2 CP
11 cellular response to iron ion GO:0071281 9.88 TFR2 TF HFE
12 response to iron ion starvation GO:1990641 9.8 HFE HAMP
13 iron ion homeostasis GO:0055072 9.8 CP HAMP HFE HJV SLC11A2 SLC40A1
14 regulation of iron ion transport GO:0034756 9.78 TF HFE
15 cellular iron ion homeostasis GO:0006879 9.62 TFRC TFR2 TF SLC40A1 SLC11A2 HJV

Molecular functions related to Hemosiderosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.85 HAMP CP ALB
2 iron ion transmembrane transporter activity GO:0005381 9.62 SLC40A1 SLC11A2
3 ferrous iron transmembrane transporter activity GO:0015093 9.56 SLC40A1 SLC11A2
4 transferrin receptor activity GO:0004998 9.46 TFRC TFR2
5 antioxidant activity GO:0016209 9.43 HP CAT ALB
6 transferrin receptor binding GO:1990459 9.1 TF HJV HFE
Sources

Sources for Hemosiderosis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....